Neurofibromatoses: Clinical Trials

41 trials for Neurofibromatoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 8 active not recruiting, 6 recruiting, 3 not yet recruiting. 41 Phase 1, 14 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 141Completed 19, Active not recruiting 8, Recruiting 6, Not yet recruiting 3, Terminated 3, Enrolling by invitation 1, Unknown 1
Phase 214Active not recruiting 5, Not yet recruiting 3, Recruiting 3, Completed 2, Terminated 1

Follow Neurofibromatoses: new trials by email Literature Review of Neurofibromatoses trials Research Report on Neurofibromatoses

Trials (filtered) newest first · largest first

All 41 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2
Phase 1 / Phase 2Not yet recruitingBeijing Tiantan Hospital302026-07-312026-07-16
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
Trineumin - Neurofibromatosis Type II, NF2
Phase 1 / Phase 2Not yet recruitingPRG Science & Technology Co., Ltd.252026-07-012026-01-23
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 1RecruitingGirish Dhall, MD302026-06-092026-10-02
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1)
Phase 1 / Phase 2RecruitingAeRang Kim452026-06-012026-07-27
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Imlygic - NF1, Neurofibromatosis
Phase 1RecruitingJohns Hopkins University102026-02-012026-05-08
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 1 / Phase 2Not yet recruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.652025-06-122025-06-17
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
PAS-004 Tablets, PAS-004 Capsule - NF1 Mutation, Neurofibroma Plexiform
Phase 1RecruitingPasithea Therapeutics Corp.562025-05-302026-10-28
Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)
Kybella - Neurofibromas, Cutaneous, Neurofibromatosis 1
Phase 1Enrolling by invitationMassachusetts General Hospital152025-04-082026-04-22
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Trametinib, Azacitidine, Fludarabine - Leukemia, Juvenile Myelomonocytic, JMML
Phase 1 / Phase 2RecruitingTherapeutic Advances in Childhood Leukemia Consortium582024-10-112026-09-04
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser - Neurofibromatosis 1
Phase 1CompletedMassachusetts General Hospital132024-03-012025-11-21
Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Kybella, Asclera - Neurofibromatosis 1
Phase 1CompletedMassachusetts General Hospital202022-12-062025-02-21
Doxycycline in Cutaneous Schwannoma (NF2)
Doxycycline Injection [Doxy] - Neurofibromatosis Type 2
Phase 1 / Phase 2Active not recruitingMassachusetts Eye and Ear Infirmary192022-09-192026-10-16
DPCP to Treat Cutaneous Neurofibromas Associated With NF1
DPCP - Cutaneous Neurofibroma
Phase 1CompletedNicholas Gulati172022-09-142024-05-06
NF-1, Nutraceutical Intervention
curcumin, high phenolic extra virgin olive oil (HP-EVOO) - Neurofibromatosis 1
Phase 1Active not recruitingMasonic Cancer Center, University of Minnesota232022-07-062026-09-23
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
Selumetinib granule formulation, Selumetinib capsule formulation - Neurofibromatosis Type 1
Phase 1 / Phase 2Active not recruitingAstraZeneca362022-01-212026-08-13
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
Abemaciclib - Neurofibromatosis 1
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)552021-11-292026-11-16
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis
TQ-B3234 capsule - Type I Neurofibromatosis
Phase 1UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.1202021-11-012021-11-04
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
AL2846 capsules - Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors
Phase 1 / Phase 2TerminatedChia Tai Tianqing Pharmaceutical Group Co., Ltd.222021-09-072024-03-21
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Selumetinib - Neurofibromatosis Type 1
Phase 1Active not recruitingAstraZeneca242021-07-212026-08-20
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
Kybella, 1064nm laser, 755nm Alexandrite Laser - Cutaneous Neurofibroma
Phase 1CompletedMassachusetts General Hospital342021-06-022025-02-21

Showing 20 of 41. Sign in to see all of them.

Narrower conditions

Neurofibromatosis 1 (30)  ·  Neurofibroma, Plexiform (9)  ·  Neurofibromatosis 2 (5)  ·  Neurofibroma (4)  ·  Neurofibrosarcoma (4)  ·  Optic Nerve Glioma (3)  ·  Astrocytoma (2)  ·  Central Nervous System Neoplasms (2)  ·  Angiofibroma (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Castleman Disease (1)  ·  Colorectal Neoplasms (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (41)  ·  Genetic Diseases, Inborn (41)  ·  Heredodegenerative Disorders, Nervous System (41)  ·  Neoplasms by Histologic Type (41)  ·  Neoplasms, Nerve Tissue (41)  ·  Neoplastic Syndromes, Hereditary (41)  ·  Nerve Sheath Neoplasms (41)  ·  Nervous System Diseases (41)  ·  Neurocutaneous Syndromes (41)  ·  Neurodegenerative Diseases (41)  ·  Neoplasms (40)  ·  Neurofibroma (37)  ·  Neuromuscular Diseases (34)  ·  Peripheral Nervous System Diseases (34)

Interventions

AZD 6244 (9)  ·  Deoxycholic Acid (4)  ·  Cetuximab (2)  ·  Lasers, Solid-State (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  Polidocanol (2)  ·  Sirolimus (2)  ·  Specimen Handling (2)  ·  Acetaminophen (1)  ·  Aminolevulinic Acid (1)  ·  Azacitidine (1)  ·  Bevacizumab (1)  ·  Biopsy (1)  ·  Carboplatin (1)  ·  Curcumin (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  AstraZeneca (5)  ·  Massachusetts General Hospital (5)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2)  ·  Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2)  ·  AeRang Kim (1)  ·  Beijing Tiantan Hospital (1)  ·  Children's Oncology Group (1)  ·  FDA Office of Orphan Products Development (1)  ·  Girish Dhall, MD (1)  ·  Great Ormond Street Hospital for Children NHS Foundation Trust (1)  ·  Harry T Whelan, MD (1)  ·  Johns Hopkins University (1)  ·  Kent Robertson (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (33)  ·  China (6)  ·  Spain (3)  ·  Japan (2)  ·  Russia (2)  ·  Australia (1)  ·  Canada (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Brigitte C Widemann, M.D. (4)  ·  Richard R Anderson, MD (3)  ·  Jason R Fangusaro (2)  ·  AeRang Kim, MD, PhD (1)  ·  Brigitte C. Widemann, MD (1)  ·  Carlos Romo, MD (1)  ·  Carrie E Bearden, PhD (1)  ·  Clay Hoerig, MD (1)  ·  D. Bradley Welling, MD, PhD (1)  ·  Darren Hargrave, MB Bch (1)  ·  Dusica Babovic-Vuksanovic, MD (1)  ·  Eric Bouffet, MD, MRCP (1)  ·  Girish Dhall, MD (1)  ·  Harry T Whelan, MD (1)

Results publications

PMID 21764821, PMID 22934754, PMID 26933802, PMID 28029918, PMID 31151904, PMID 32187457, PMID 33470897, PMID 33641042, PMID 35170228, PMID 35410754, PMID 35467749, PMID 37115514, PMID 37311055, PMID 37400844, PMID 38721358, PMID 38869947, PMID 40709016, PMID 41139346, PMID 41389341, PMID 41592259, PMID 42394972, PMID 42540436

NIH funding

UM1CA081457 (2), U01CA081457 (1)